• Avalo Therapeutics Chief Medical Officer Doyle Mittie sold 3,000 common shares on May 15 at USD 18.76.
• The sale followed the exercise of 3,000 stock options at USD 12.65 on the same day.
• Mittie ended the day with 3,622 common shares held directly.
• Derivative holdings included 128,625 stock options outstanding following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001918845-26-000012), on May 19, 2026, and is solely responsible for the information contained therein.